Celltrion Launches 'Omriclo' as First-Mover in Brazil

Accelerating Expansion into Latin America
by Securing Early Market Entry

Celltrion announced on November 27 that it has launched 'Omriclo' (ingredient: omalizumab), its chronic idiopathic urticaria treatment, in Brazil, the largest pharmaceutical market in Latin America.

Omriclo is the first omalizumab biosimilar to be launched in Brazil, making it a 'first mover' product. The 150mg dosage has been released first, and the company plans to expand treatment options for patients by introducing a 75mg product early next year.

Celltrion's chronic idiopathic urticaria treatment 'Omriclo'. Celltrion

Celltrion's Brazilian subsidiary has been actively promoting the product's competitiveness and stable supply capabilities to local pharmaceutical buyers and medical institutions even before the launch of Omriclo, working to raise brand awareness. Given the high level of trust and preference among Brazilian healthcare professionals who have prescribed Celltrion products for many years, the company expects Omriclo to quickly establish itself in the market.

Marketing activities targeting healthcare professionals for Omriclo are already in full swing. On November 13 (local time), Celltrion's Brazilian subsidiary participated in the ASBAI (Brazilian Association of Allergy and Immunology) conference held in Brazil, where it presented Omriclo's clinical data and treatment convenience to local medical professionals, generating significant interest and positive feedback.

Celltrion's major products continue to show strong growth in Brazil, raising expectations for the success of newly launched products. As of the second quarter of this year, 'Truxima' (ingredient: rituximab), a blood cancer treatment, held about 80% market share in Brazil's private sector (according to local market data), while 'Remsima' (ingredient: infliximab), an autoimmune disease treatment, maintained a 60% market share in the same segment.

Building on the performance of its existing products, Celltrion plans to ensure the successful market entry of Omriclo and other follow-up products. The company aims to strengthen its position by expanding its product portfolio beyond Brazil to the entire Latin American market.

Kang Kyungdu, Head of Celltrion's Latin America division, stated, "Omriclo, as the first-mover omalizumab biosimilar launched in Brazil, will leverage the advantage of early market entry to rapidly expand prescriptions. Starting with Brazil, we will actively expand the number of countries selling Omriclo in Latin America from next year, further solidifying our market position."

Meanwhile, Omriclo, developed by Celltrion, is a treatment for chronic idiopathic urticaria and asthma. The original drug, Xolair, recorded global sales of approximately 6.4992 trillion won last year, making it a blockbuster pharmaceutical product.

This content was produced with the assistance of AI translation services.